Addex Therapeutics Balance Sheet Health
Financial Health criteria checks 1/6
Addex Therapeutics has a total shareholder equity of CHF-1.4M and total debt of CHF0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CHF3.3M and CHF4.7M respectively.
Key information
0%
Debt to equity ratio
CHF 0
Debt
| Interest coverage ratio | n/a |
| Cash | CHF 1.63m |
| Equity | -CHF 1.37m |
| Total liabilities | CHF 4.71m |
| Total assets | CHF 3.34m |
Recent financial health updates
Recent updates
Addex, Indivior expand team up to develop therapies for substance use disorders
Aug 15Addex stock falls 11% amid $4.2M equity financing with Armistice
Jul 22Addex Therapeutics CEO Tim Dyer - Emerging Drugs For Central Nervous System (Video)
Oct 21Addex, Janssen initiate Phase 2 study of ADX71149 for epilepsy
Jun 07Addex Therapeutics reports Q1 results
May 05Addex drops 23% after pricing share offering
Jan 07Addex Therapeutics files to sell $10M of ADS
Dec 14Addex Therapeutics reports Q3 results
Nov 03Financial Position Analysis
Short Term Liabilities: ADXN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ADXN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ADXN is debt free.
Reducing Debt: ADXN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADXN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ADXN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 21.3% each year